EV is an antibody–drug conjugate (ADC) composed of the antibody enhortumab vedotin recognizing nectin-4 expressed on cancer cells and protease-cleavable linker-bound monomethyl auristatin E (MMAE), which disrupts microtubule formation [23]. This evidence concerns the gene NECTIN4 and cancer.